I got about 2 ounces of these from Telluride CO during the annual mushroom festival they have there every August, Sept.
They used to be called 'Bezerker' mushrooms by the Vikings, they used to eat these before going into battle. Amantia were the first ever outlawed drug, being outlawed in Scandinavia in 1099 for being too dangerous. Lots of fellow Vikings were killed by their freinds in 'Freindly Fire' incidents. The guys hacking away under the influence of the Amantia could not recognise freind from foe !
In doing research on the Amantia, I discovered that the toxic dosage was very close to the effect dosage and I got cold feet. Didn't eat um. Apparently, the Amantia was used by the shamans of ancient Switzerland. The way araound the toxicity was that the preist would eat the Amantia, then after a little while, would piss into a vessel, and the followed would then drink the urine. That way they consumed a measure dose, filter by the priest. Sound like fun, unfortunately, there was no one around who would do that for me and I really didn't feel like drinking anyone's urine....
BillyWarhol Pro User says*
The effects of psilocybin are often pleasant, even ecstatic, including a deep sense of connection to others, confusion, hilarity, and a general feeling of connection to nature and the universe. Difficult trips may occur when psychedelic compounds are taken in a non-supportive or inadequate environment, by an inexperienced person, or in an unexpectedly high dose (see: set and setting).
At low doses, hallucinatory effects occur, including walls that seem to breathe, a vivid enhancement of colors and the animation of organic shapes. At higher doses, experiences tend to be less social and more entheogenic, often catalyzing intense spiritual experiences. For example, in the Marsh Chapel Experiment, which was run by a graduate student at Harvard Divinity School under the supervision of Timothy Leary, almost all of the graduate degree divinity student volunteers who received psilocybin reported profound religious experiences. (A brief video about the Marsh Chapel experiment can be viewed here.)
In 2006, a group of researchers from Johns Hopkins School of Medicine led by Roland R Griffiths conducted an experiment assessing the degree of mystical experience and attitudinal effects of the psilocybin experience; this report was published in the journal Psychopharmacology. Thirty-six volunteers without prior experience with hallucinogens were given psilocybin and methylphenidate (Ritalin) in separate sessions, the methylphenidate sessions serving as a control and active placebo; the tests were double-blind, with neither the subject nor the administrator knowing which drug was being administered. The degree of mystical experience was measured using a questionnaire on mystical experience developed by Ralph W Hood; 61% of subjects reported a "complete mystical experience" after their psilocybin session, while only 13% reported such an outcome after their experience with methylphenidate. Two months after taking psilocybin, 79% of the participants reported moderately to greatly increased life satisfaction and sense of well-being. About 36% of participants also had a strong to extreme “experience of fear” or dysphoria (eg, a “bad trip”) at some point during the psilocybin session (which was not reported by any subject during the methylphenidate session), with about one-third of these (13% of the total) reporting that this dysphoria dominated the entire session. These negative effects were reported to be easily managed by the researchers and did not have a lasting negative effect on the subject’s sense of well-being.   This research was widely covered in the major media outlets.
A very small number of people are unusually sensitive to psilocybin's effects, where doses as little as 0.25 grams of dried Psilocybe cubensis mushrooms (normally a threshold dose of around 2 mg psilocybin) can result in effects usually associated with medium and high doses. Likewise, there are some people who require relatively high doses of psilocybin to gain low-dose effects. Individual brain chemistry and metabolism plays a large role in determining a person's response to psilocybin.